Insider Monkey
Novo Nordisk (NVO) Faces Pricing Pressure While Defending Wegovy Franchise and Advancing Oral GLP-1s
📉
AI Sentiment
Negative
3/10
Hims & Hers Health Inc. News
Latest updates and market news for HIMS
11 news
Feb 4 - Feb 10, 2026
Page 1
Simply Wall St.
Novo Nordisk Tests Obesity Drug Moat As Regulators Target GLP 1 Copycats
âž–
AI Sentiment
Neutral
5/10
Associated Press Finance
Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill
📉
AI Sentiment
Negative
2/10
Investor's Business Daily
Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown
📉
AI Sentiment
Negative
2/10
Barrons.com
Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny
📉
AI Sentiment
Negative
3/10
Financial Times
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
📉
AI Sentiment
Negative
3/10
BioPharma Dive
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
📉
AI Sentiment
Negative
3/10
Benzinga
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
📉
AI Sentiment
Negative
3/10
Investor's Business Daily
Hims & Hers Pops After Scoring A Cancer-Screening Deal With Grail
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care
📈
AI Sentiment
Highly Positive
9/10
StockStory
1 Volatile Stock for Long-Term Investors and 2 We Brush Off
âž–
AI Sentiment
Neutral
4/10
Share this news page